Efficacy and Safety of Ivabradine in the Treatment of Chronic Heart Failure in the Context of the New Quadrilateral
10.3969/j.issn.1000-3614.2024.03.007
- VernacularTitle:"新四联"背景下伊伐布雷定治疗慢性心力衰竭的有效性和安全性
- Author:
Congling CHEN
1
,
2
;
Han WU
;
Ruobin ZHANG
;
Jiachen YING
;
Xi LAN
;
Jinping ZHANG
;
Xian YANG
Author Information
1. 南京鼓楼医院 药学部,南京 210008
2. 中国药科大学 基础医学与临床药学学院,南京 211198
- Keywords:
chronic heart failure;
ivabradine;
new quadruple;
prognosis
- From:
Chinese Circulation Journal
2024;39(3):256-260
- CountryChina
- Language:Chinese
-
Abstract:
Objectives:To assess the effectiveness and safety of ivabradine for the treatment of chronic heart failure in the context of the new quadruple combination. Methods:Clinical data of 656 chronic heart failure patients hospitalized in Nanjing Drum Tower Hospital from March 2021 to June 2022 were retrospectively collected,and the patients were divided into control group(n=361)and observation group(n=295)according to ivabradine use,and both groups were treated with the new quadruple drug therapy.Propensity score matching was performed,268 patients in the observation group and 268 patients in the control group were successfully matched.The effectiveness(primary endpoint was the composite endpoint of cardiovascular death and rehospitalisation for worsening heart failure within 1 year of discharge;secondary endpoints were rehospitalisation for worsening heart failure,all-cause rehospitalisation,cardiovascular death,and all-cause death)and safety outcome measures(including bradycardia,atrial fibrillation,blurred vision,renal impairment,and hypertension)were compared between the two groups at 1 year after treatment. Results:After matching,there were no statistically significant differences at baseline characteristics between the two groups.Kaplan-Meier survival curve showed that the occurrence rates of primary endpoints(P=0.031),readmission for worsening heart failure(P=0.020),and all-cause readmission(P=0.036)were lower in the observation group than in the control group.Multivariate Cox proportional hazard regression analysis showed that the occurrence rates of primary endpoint events(P=0.045)and readmission for heart failure worsening(P=0.028)were lower in the observation group than in the control group. Conclusions:The ivabradine use on top of the new quadruple therapy regimen in patients with chronic heart failure is beneficial to improve one-year prognosis with favorable safety profile.
